Detalhe da pesquisa
1.
Noradrenergic control of neurobehavior in human binge-eating disorder and obesity (NOBEAD): A smartphone-supported behavioral emotion regulation intervention study protocol integrating molecular brain imaging.
Int J Eat Disord
; 57(1): 206-220, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37941314
2.
(+)-[18F]Flubatine as a novel α4ß2 nicotinic acetylcholine receptor PET ligand-results of the first-in-human brain imaging application in patients with ß-amyloid PET-confirmed Alzheimer's disease and healthy controls.
Eur J Nucl Med Mol Imaging
; 48(3): 731-746, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32935187
3.
Sigma-1 and dopamine D2/D3 receptor occupancy of pridopidine in healthy volunteers and patients with Huntington disease: a [18F] fluspidine and [18F] fallypride PET study.
Eur J Nucl Med Mol Imaging
; 48(4): 1103-1115, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32995944
4.
Central noradrenaline transporter availability is linked with HPA axis responsiveness and copeptin in human obesity and non-obese controls.
Stress
; 22(1): 93-102, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30369292
5.
Cognitive correlates of α4ß2 nicotinic acetylcholine receptors in mild Alzheimer's dementia.
Brain
; 141(6): 1840-1854, 2018 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29672680
6.
Noradrenaline transporter availability on [11C]MRB PET predicts weight loss success in highly obese adults.
Eur J Nucl Med Mol Imaging
; 45(9): 1618-1625, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29627935
7.
Test-retest measurements of dopamine D1-type receptors using simultaneous PET/MRI imaging.
Eur J Nucl Med Mol Imaging
; 44(6): 1025-1032, 2017 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-28197685
8.
Central noradrenaline transporter availability in highly obese, non-depressed individuals.
Eur J Nucl Med Mol Imaging
; 44(6): 1056-1064, 2017 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-28066877
9.
Central serotonin transporter availability in highly obese individuals compared with non-obese controls: A [(11)C] DASB positron emission tomography study.
Eur J Nucl Med Mol Imaging
; 43(6): 1096-104, 2016 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-26577939
10.
Evaluation of the Enantiomer Specific Biokinetics and Radiation Doses of [(18)F]Fluspidine-A New Tracer in Clinical Translation for Imaging of σ1 Receptors.
Molecules
; 21(9)2016 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27598110
11.
First-in-human PET quantification study of cerebral α4ß2* nicotinic acetylcholine receptors using the novel specific radioligand (-)-[(18)F]Flubatine.
Neuroimage
; 118: 199-208, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26037057
12.
Altered serotonin transporter availability in patients with multiple sclerosis.
Eur J Nucl Med Mol Imaging
; 41(5): 827-35, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24562640
13.
Imaging of the brain serotonin transporters (SERT) with 18F-labelled fluoromethyl-McN5652 and PET in humans.
Eur J Nucl Med Mol Imaging
; 39(6): 1001-11, 2012 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-22349718
14.
PET Imaging of Cholinergic Neurotransmission in Neurodegenerative Disorders.
J Nucl Med
; 63(Suppl 1): 33S-44S, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35649648
15.
Availability of Central α4ß2* Nicotinic Acetylcholine Receptors in Human Obesity.
Brain Sci
; 12(12)2022 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36552108
16.
Central Serotonin/Noradrenaline Transporter Availability and Treatment Success in Patients with Obesity.
Brain Sci
; 12(11)2022 Oct 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-36358364
17.
Impact of EEG-vigilance on brain glucose uptake measured with [(18)F]FDG and PET in patients with depressive episode or mild cognitive impairment.
Neuroimage
; 56(1): 93-101, 2011 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21276863
18.
The serotonin transporter availability in untreated early-onset and late-onset patients with obsessive-compulsive disorder.
Int J Neuropsychopharmacol
; 14(5): 606-17, 2011 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-21232166
19.
Individualized quantification of brain ß-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer's disease and healthy controls.
Eur J Nucl Med Mol Imaging
; 38(9): 1702-14, 2011 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-21547601
20.
Central Noradrenergic Neurotransmission and Weight Loss 6 Months After Gastric Bypass Surgery in Patients with Severe Obesity.
Obes Surg
; 31(11): 4868-4876, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34414548